Neal Shore, MD, Carolina Urologic Research Center

Articles

Future Directions With PSMA Ligand–Directed Therapies

August 6th 2021

Highlights of potential future applications of PSMA ligand–directed therapies in prostate cancer.

The VISION Study of 177Lu-PSMA-617 in mCRPC

August 6th 2021

Results of the phase 3 VISION study of 177Lu-PSMA PET in advanced prostate cancer are described.

Use of PSMA PET Scans in Advanced Prostate Cancer

July 30th 2021

Dr Neal Shore explains the clinical implications of PSMA PET scans in advanced prostate cancer.

Diagnostic and Therapeutic Applications of PSMA in Prostate Cancer

July 28th 2021

An overview of the diagnostic and therapeutic applications of PSMA in prostate cancer is presented.

Genotypic and Phenotypic Biomarkers in Prostate Cancer

July 23rd 2021

A discussion of phenotypic and genotypic biomarkers found in prostate cancer and their implications.

Prostate Cancer Disease Complexity and Testing

July 23rd 2021

Neal Shore, MD, discusses the complexity of prostrate cancer and factors to consider when determining management strategies.

Rapid Readouts: Extended Follow-up From the Phase 3 ARAMIS trial

June 30th 2021

Neal Shore, MD, presents data on the tolerability of and responses to darolutamide (DARO) as seen in the extended follow-up of the phase 3 ARAMIS trial of DARO treatment in men with high-risk, nonmetastatic, castration-resistant prostate cancer. The results were reported at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Rapid Readouts: Treatment Preference Results From the Phase 2 ODENZA Trial

June 30th 2021

Neal Shore, MD, presents data on treatment preferences from the phase 2 ODENZA trial of darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer. The results were reported at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Advanced Prostate Cancer: Remaining Challenges

March 9th 2021

Experts discuss challenges and unmet needs in men with advanced prostate cancer who are undergoing treatment with androgen deprivation therapy.

Risk Factors in Advanced Prostate Cancer

March 9th 2021

Stephen Freedland, MD, discusses risk factors involved in men with advanced prostate cancer who receive androgen deprivation therapy.

Advanced Prostate Cancer: New Findings From ASCO GU 2021

March 8th 2021

Dan George, MD, reviews new findings in advanced prostate cancer presented at ASCO GU 2021.

The First Oral GNRH Receptor Antagonist for Advanced Prostate Cancer

March 8th 2021

Neal Shore, MD, discusses the recent FDA approval of the first oral GNRH receptor antagonist, relugolix, for men with advanced prostate cancer, along with data from the phase 3 HERO trial.